-
NICE UK approves Roche's PD-L1 mono-antitecentriq for treatment of triple-negative breast cancer
Time of Update: 2020-05-29
Following Roche's 'improved offer', NICE UK now supports the combination of PD-L1 mono-antitecentriq (atezolizumab) and nab-yew alcohol for PD-L1-positive advanced triple-negative breast cancer Te
-
A major breakthrough! Nature: T-cell immunotherapy completely cures advanced cancer
Time of Update: 2020-05-29
The best medicine for humans is his own immune system If we use it thoroughly, we can even beat the of terminal cancer! an article published on June 4th in the leading journal Nature Medicine,
-
Cell Death Dis: ZNF750 downsetting activates DANCR/miR-4707-3p/FOXC2 pathway promotes angiogenesis of esophageal squamous cell carcinoma
Time of Update: 2020-05-29
Esophageal squamous cell carcinoma (ESCC) is one of the deadliest malignancies in esophageal cancer, with more than 477,900 new cases and 375,000 deaths each year in China Although chemotherapy and
-
Lancet Oncol: Pym mono-anti-combination therapy first-line treatment of HER2-positive metastatic esophageal gastric cancer
Time of Update: 2020-05-29
Adding qutoberitosic resistance to first-line chemotherapy can improve the overall survival rate of HER2-positive metastatic gastric cancer patients Recently, researchers evaluated the efficacy of
-
Stocktaking: Blood Research Selected on May 21, 2020
Time of Update: 2020-05-29
1 Non-myoglobin IIA mutation and MYH9-related thrombocytopenia https://doi.org/10.1182/blood.2019003064 cytoblasts (MKs) are precursor cells of platelets, non-muscular myoglobin II (MYH9) mut
-
State Drug Administration priority review and approval, a new generation of domestic lung cancer innovative drugs listed
Time of Update: 2020-05-29
A new generation of domestic lung cancer innovative drug "Ametini" officially listed May 10, a reporter learned the news from the Haussen Pharmaceutical Research and Development Center in Zhangji
-
Professor Zhao Mingfang: Dakortini has its own characteristics and advantages, strengthen the understanding of drugs and toxicity management, is expected to help patients achieve high-quality long-term survival
Time of Update: 2020-05-29
In May 2019, the second representative of the thin growth factor receptor tyrosine kinase inhibitor (EGFR TKI) Dacostini was officially approved in China, becoming the first-line treatment option f
-
Cell Death Dis: Anti-cancer effect of statins in p53 mutant T-type lymphoma
Time of Update: 2020-05-29
Long-standing research has found that statins may have anti-tumor activity There is currently some epidemiological evidence that statin use is associated with reduced mortality rates for many distr
-
Blood: Anticoagulase replaces the effect of preventing venous thrombosis
Time of Update: 2020-05-29
Patients receiving treatment for acute lymphoblastic leukemia (ALL) are at risk of thrombosis, in part because of the use of L-thymidamidase (L-ASP) Anticoagulase (AT) replacement has been recommen
-
Nat Cell Bio: Mysterious protein found in patients with advanced breast cancer that could be used to treat breast cancer
Time of Update: 2020-05-29
Introduction: The cause of breast cancer is not yet clear, early breast cancer often does not have typical symptoms and signs, not easy to attract attention, but the incidence of breast cancer is t
-
Man suffers from huge complex kidney tumour Guangdong hospital successfully cuts tumor and preserves kidney
Time of Update: 2020-05-29
Sun Yat-sen University affiliated with the first hospital said on the 14th, the hospital's urology professor Luo Junhang team used Da Vinci robot-assisted surgery technology and improved renal vasc
-
Oncologist: Professor Xu Jianmin found that CERR scores can better assess relapse after liver metastasis of colorectal cancer
Time of Update: 2020-05-29
At present, surgical removal is the most important milestone in the treatment of colon cancer liver metastasis, 5 years of survival can reach more than 50% difficulties of rectal liver metastasis
-
2020 AACR: Multifunction lysoid virus BT-001 has strong activity on solid tumors
Time of Update: 2020-05-29
Biotech companies BioInvent and Transgene today released preclinical data on the multifunction lysoid virus BT-001 for cancer treatment, demonstrating the broad therapeutic potential of BT-001 for
-
Cell Death Dis: A New Mechanism for Colorectal Cancer Metastay
Time of Update: 2020-05-29
Colorectal cancer (CRC) is the third most commonly diagnosed malignant tumor and the third highest cancer mortality rate worldwide Tumor metastasis is the leading cause of death in patients at the
-
Boxei Squibb announces CheckMate870 clinical study reaches key research end, no new safety signals found
Time of Update: 2020-05-29
On May 15, 2020, TimeMes Guibao (NYSE: BMY) announced that the CheckMate 870 study had reached its main end in clinical research CheckMate 870 is an open labeled Phase IIIB clinical study designed
-
Brit J Cancer: Relationship between female exogenous hormones and reproductive factors and risk of biliary cancer in the liver
Time of Update: 2020-05-29
Hepatic biliary tube cancer (ICC) originates from bile duct cells in the liver's biliary tube and is the second most common type of liver cancer Bile duct cells express both estrogen alpha and beta
-
NICE UK supports Roche's ADC drug Kadcyla Enmetodo monosantia to treat HER2-positive early breast cancer
Time of Update: 2020-05-29
Roche's antibody drug conjugal (ADC) Kadcyla (trastuzumab Emtansine, Enmetotoe) has been recommended by the National Institute for Health and Clinical Technology Optimization (NICE) to treat HER2-p
-
Stocktaking: May 7, 2020 Blood Research Select
Time of Update: 2020-05-29
1 The high-fat diet delays the production of plasma lysozyme in a thrombosis-regulated protein-dependent manner https://doi.org/10.1182/blood.2019004267 https://doi.org/10.1182/blood.2019004267
-
Antib Ther: Clinical application potential for CD47-SIRP alpha macrophage immunophhagic immune checkpoint pathway target blocking
Time of Update: 2020-05-29
Recently, Antibody Therapeutics, a journal of the Chinese Antibody Association and published by Oxford University Press, published a review paper entitled "Macrophage checkpoint blockade: a perspec
-
FDA approves AstraZeneca/Merck's PARP inhibitor Lynparza to treat prostate cancer
Time of Update: 2020-05-29
AstraZeneca and Merck announced that the FDA has approved its PARP inhibitor Lynparza (olaparib) for the treatment of patients with homogenous resusandive (HRR) gene mutations, and the progression
